EGFR CELL EXPRESSION IN BLADDER WASHINGS AS A RISK MARKER TOOL IN NON MUSCLE-INVASIVE BLADDER CANCER. PRELIMINARY EXPERIENCE

Risultato della ricerca: Other

Abstract

INTRODUCTION AND OBJECTIVES: Up to day, EGFRexpression has been determined mainly in tissue specimens of muscleinvasivebladder cancer and its overexpression has been associatedwith worse prognosis and shorter survival. Urothelial EGFR status afterNMIBC transurethral resection (TUR) could indicate the risk of recurrenceand progression. We investigated the feasibility of EGFR measurementin bladder washings of patients undergoing intravesicaladjuvant therapy for NMIBC and its usefulness in identifying risksubgroups.METHODS: Our prospective study included patients after TURof NMIBC and healthy controls. A cellular pellet was obtained frombladder washing, and RNA extraction performed by miRNeasy Mini Kit(Qiagen). Good quality of RNA was checked. The cDNA obtainedfrom RNA was used to perform a gene expression analysis by a RealTime PCR, according to the method of the comparative quantification(DDCt) with an endogenous control (Cyclophilin). Every reaction wasset in triplicate as a guarantee of quality. Patients were grouped for EAUrisk class and maintained in follow-up. The EGFR expressions werestatistically analyzed according to EAU risk groups and to patients0outcome. EGFR gene expression values were expressed in FOLDs ofchange compared to healthy controls (EGFR¼1).RESULTS: Fifty-eight patients and 21 healthy age-matchedcontrols were entered. An adequate cellular pellet was obtained in 50patients (86.2%) showing a median EGFR expression of 2.0 folds (IQR0.6-4.3, p¼0.0004). After TUR and adjuvant intravesical therapy, 22(55%) out of 40 high-risk patients, showed EGFR decrease to 1.3 folds(IQR 0.9-1.5), while 18 (45%) showed elevated EGFR, median 4.7 (IQR4.1-11.6). At 25 months median follow-up (IQR 19.0-34.8), 20 (40%)patients recurred and 6 (12%) progressed. Among patients with orwithout EGFR gene increase, 9 (22.5%) and 5 (12.5%) recurred and 5(12.5%) and 1 (2.5%) progressed, respectively.CONCLUSIONS: In our experience EGFR expression measurementwas feasible in more than 85% of patients and resultedrelated to EAU risk classes for recurrence and progression, showingdifferent behavior during intravesical therapy. It was possible to identifya subgroup of high risk patients overexpressing EGFR in spite ofintravesical adjuvant therapy. EGFR evaluation in bladder washingcould represent a repeatable and useful tool to identify a subgroup ofpatients at risk for progression unresponsive to intravesical adjuvanttherapy and candidate to early radical cystectomy
Lingua originaleEnglish
Pagine571-571
Numero di pagine1
Stato di pubblicazionePublished - 2017

Fingerprint

Urinary Bladder Neoplasms
Urinary Bladder
Muscles
erbB-1 Genes
RNA
Cyclophilins
Gene Expression
Cystectomy
Therapeutics
Complementary DNA
Prospective Studies
Recurrence
Polymerase Chain Reaction
Survival

Cita questo

@conference{dc6e71a2e0604e08b173e1e8ff3fd00b,
title = "EGFR CELL EXPRESSION IN BLADDER WASHINGS AS A RISK MARKER TOOL IN NON MUSCLE-INVASIVE BLADDER CANCER. PRELIMINARY EXPERIENCE",
abstract = "INTRODUCTION AND OBJECTIVES: Up to day, EGFRexpression has been determined mainly in tissue specimens of muscleinvasivebladder cancer and its overexpression has been associatedwith worse prognosis and shorter survival. Urothelial EGFR status afterNMIBC transurethral resection (TUR) could indicate the risk of recurrenceand progression. We investigated the feasibility of EGFR measurementin bladder washings of patients undergoing intravesicaladjuvant therapy for NMIBC and its usefulness in identifying risksubgroups.METHODS: Our prospective study included patients after TURof NMIBC and healthy controls. A cellular pellet was obtained frombladder washing, and RNA extraction performed by miRNeasy Mini Kit(Qiagen). Good quality of RNA was checked. The cDNA obtainedfrom RNA was used to perform a gene expression analysis by a RealTime PCR, according to the method of the comparative quantification(DDCt) with an endogenous control (Cyclophilin). Every reaction wasset in triplicate as a guarantee of quality. Patients were grouped for EAUrisk class and maintained in follow-up. The EGFR expressions werestatistically analyzed according to EAU risk groups and to patients0outcome. EGFR gene expression values were expressed in FOLDs ofchange compared to healthy controls (EGFR¼1).RESULTS: Fifty-eight patients and 21 healthy age-matchedcontrols were entered. An adequate cellular pellet was obtained in 50patients (86.2{\%}) showing a median EGFR expression of 2.0 folds (IQR0.6-4.3, p¼0.0004). After TUR and adjuvant intravesical therapy, 22(55{\%}) out of 40 high-risk patients, showed EGFR decrease to 1.3 folds(IQR 0.9-1.5), while 18 (45{\%}) showed elevated EGFR, median 4.7 (IQR4.1-11.6). At 25 months median follow-up (IQR 19.0-34.8), 20 (40{\%})patients recurred and 6 (12{\%}) progressed. Among patients with orwithout EGFR gene increase, 9 (22.5{\%}) and 5 (12.5{\%}) recurred and 5(12.5{\%}) and 1 (2.5{\%}) progressed, respectively.CONCLUSIONS: In our experience EGFR expression measurementwas feasible in more than 85{\%} of patients and resultedrelated to EAU risk classes for recurrence and progression, showingdifferent behavior during intravesical therapy. It was possible to identifya subgroup of high risk patients overexpressing EGFR in spite ofintravesical adjuvant therapy. EGFR evaluation in bladder washingcould represent a repeatable and useful tool to identify a subgroup ofpatients at risk for progression unresponsive to intravesical adjuvanttherapy and candidate to early radical cystectomy",
author = "Alchiede Simonato and Vincenzo Serretta and Antonina Cangemi and Marco Vella and Antonio Russo",
year = "2017",
language = "English",
pages = "571--571",

}

TY - CONF

T1 - EGFR CELL EXPRESSION IN BLADDER WASHINGS AS A RISK MARKER TOOL IN NON MUSCLE-INVASIVE BLADDER CANCER. PRELIMINARY EXPERIENCE

AU - Simonato, Alchiede

AU - Serretta, Vincenzo

AU - Cangemi, Antonina

AU - Vella, Marco

AU - Russo, Antonio

PY - 2017

Y1 - 2017

N2 - INTRODUCTION AND OBJECTIVES: Up to day, EGFRexpression has been determined mainly in tissue specimens of muscleinvasivebladder cancer and its overexpression has been associatedwith worse prognosis and shorter survival. Urothelial EGFR status afterNMIBC transurethral resection (TUR) could indicate the risk of recurrenceand progression. We investigated the feasibility of EGFR measurementin bladder washings of patients undergoing intravesicaladjuvant therapy for NMIBC and its usefulness in identifying risksubgroups.METHODS: Our prospective study included patients after TURof NMIBC and healthy controls. A cellular pellet was obtained frombladder washing, and RNA extraction performed by miRNeasy Mini Kit(Qiagen). Good quality of RNA was checked. The cDNA obtainedfrom RNA was used to perform a gene expression analysis by a RealTime PCR, according to the method of the comparative quantification(DDCt) with an endogenous control (Cyclophilin). Every reaction wasset in triplicate as a guarantee of quality. Patients were grouped for EAUrisk class and maintained in follow-up. The EGFR expressions werestatistically analyzed according to EAU risk groups and to patients0outcome. EGFR gene expression values were expressed in FOLDs ofchange compared to healthy controls (EGFR¼1).RESULTS: Fifty-eight patients and 21 healthy age-matchedcontrols were entered. An adequate cellular pellet was obtained in 50patients (86.2%) showing a median EGFR expression of 2.0 folds (IQR0.6-4.3, p¼0.0004). After TUR and adjuvant intravesical therapy, 22(55%) out of 40 high-risk patients, showed EGFR decrease to 1.3 folds(IQR 0.9-1.5), while 18 (45%) showed elevated EGFR, median 4.7 (IQR4.1-11.6). At 25 months median follow-up (IQR 19.0-34.8), 20 (40%)patients recurred and 6 (12%) progressed. Among patients with orwithout EGFR gene increase, 9 (22.5%) and 5 (12.5%) recurred and 5(12.5%) and 1 (2.5%) progressed, respectively.CONCLUSIONS: In our experience EGFR expression measurementwas feasible in more than 85% of patients and resultedrelated to EAU risk classes for recurrence and progression, showingdifferent behavior during intravesical therapy. It was possible to identifya subgroup of high risk patients overexpressing EGFR in spite ofintravesical adjuvant therapy. EGFR evaluation in bladder washingcould represent a repeatable and useful tool to identify a subgroup ofpatients at risk for progression unresponsive to intravesical adjuvanttherapy and candidate to early radical cystectomy

AB - INTRODUCTION AND OBJECTIVES: Up to day, EGFRexpression has been determined mainly in tissue specimens of muscleinvasivebladder cancer and its overexpression has been associatedwith worse prognosis and shorter survival. Urothelial EGFR status afterNMIBC transurethral resection (TUR) could indicate the risk of recurrenceand progression. We investigated the feasibility of EGFR measurementin bladder washings of patients undergoing intravesicaladjuvant therapy for NMIBC and its usefulness in identifying risksubgroups.METHODS: Our prospective study included patients after TURof NMIBC and healthy controls. A cellular pellet was obtained frombladder washing, and RNA extraction performed by miRNeasy Mini Kit(Qiagen). Good quality of RNA was checked. The cDNA obtainedfrom RNA was used to perform a gene expression analysis by a RealTime PCR, according to the method of the comparative quantification(DDCt) with an endogenous control (Cyclophilin). Every reaction wasset in triplicate as a guarantee of quality. Patients were grouped for EAUrisk class and maintained in follow-up. The EGFR expressions werestatistically analyzed according to EAU risk groups and to patients0outcome. EGFR gene expression values were expressed in FOLDs ofchange compared to healthy controls (EGFR¼1).RESULTS: Fifty-eight patients and 21 healthy age-matchedcontrols were entered. An adequate cellular pellet was obtained in 50patients (86.2%) showing a median EGFR expression of 2.0 folds (IQR0.6-4.3, p¼0.0004). After TUR and adjuvant intravesical therapy, 22(55%) out of 40 high-risk patients, showed EGFR decrease to 1.3 folds(IQR 0.9-1.5), while 18 (45%) showed elevated EGFR, median 4.7 (IQR4.1-11.6). At 25 months median follow-up (IQR 19.0-34.8), 20 (40%)patients recurred and 6 (12%) progressed. Among patients with orwithout EGFR gene increase, 9 (22.5%) and 5 (12.5%) recurred and 5(12.5%) and 1 (2.5%) progressed, respectively.CONCLUSIONS: In our experience EGFR expression measurementwas feasible in more than 85% of patients and resultedrelated to EAU risk classes for recurrence and progression, showingdifferent behavior during intravesical therapy. It was possible to identifya subgroup of high risk patients overexpressing EGFR in spite ofintravesical adjuvant therapy. EGFR evaluation in bladder washingcould represent a repeatable and useful tool to identify a subgroup ofpatients at risk for progression unresponsive to intravesical adjuvanttherapy and candidate to early radical cystectomy

UR - http://hdl.handle.net/10447/265454

M3 - Other

SP - 571

EP - 571

ER -